• Home
  • Find a Pharmacy
  • Health News
  • Medications
  • Conditions
  • RxCoupons
  • Pharmacy Solutions
RxWiki - Home
Find a Pharmacy Health News Medications Conditions RxCoupons Pharmacy Solutions

News Releases

DOD Study Supports Benefit-Risk Profile of Pradaxa for AFib
Ridgefield, CT, November 17, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a U.S. Department of Defense cohort analysis of the Military Health System database showing that non-valvular atrial fibrillation (NVAF) patients treated with Pradaxa® (dabigatran etexilate mesylate) in routine clinical care experienced reduced rates of stroke, major bleeding, death and other types of bleeding, along with increased lower gastrointestinal (GI) bleeding, compared to patients treated with warfarin.
Drug Application for Atrial Fibrillation
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for Eliquis ( apixaban ), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

REFINE

  • conditions
      • (-) Remove Cardiovascular filter Cardiovascular
        • (-) Remove Atrial Fibrillation filter Atrial Fibrillation
        • Stroke (1) Apply Stroke filter
All information on this site is provided "as-is" for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health. The use of any information on this site is solely at your own risk.
  • Find a Pharmacy
  • Health News
  • Medications
  • Conditions
  • RxCoupons
  • Mobile App
  • Pharmacy Solutions
  • Terms and Conditions
  • Privacy Policy
  • Contact
  • Home
    Facebook
  • Home
    Google Plus
  • Home
    Twitter
© 2020 Digital Pharmacist Inc.